KIA
EVH icon

Kraematon Investment Advisors’s Evolent Health EVH Stock Holding History

Kraematon Investment Advisors’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20
Closed -$562 – 124
2022
Q4 		$562 Buy
+20
New +$573 ﹤0.01% 256

Other funds holding EVH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kraematon Investment Advisors's EVH Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Evolent Health (EVH) in Q1 2023, closing a stake of 20 shares — an estimated $562 sold.

Kraematon Investment Advisors first reported a position in EVH in Q4 2022 and held it in 1 quarter. The position peaked at $562 in Q4 2022. 240 funds tracked by Wall St. Rank hold EVH as of Q1 2023.

  • Kraematon Investment Advisors reported no remaining Evolent Health position as of Q1 2023 after selling out during the quarter.
  • Kraematon Investment Advisors sold 20 Evolent Health shares in Q1 2023, an estimated $562.
  • Kraematon Investment Advisors first reported a position in Evolent Health in Q4 2022 and held it in 1 quarter.
  • Kraematon Investment Advisors's Evolent Health position peaked at $562 in Q4 2022.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.